CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 7 No. 5
 

Grape Seed Extract Has Cytotoxic Effects on Human Cancer Cells

May 1, 1998

NEW ORLEANS--An extract derived from the seeds of red grapes, currently available as a dietary supplement (Activin), has been shown to reduce tumor cell growth in human breast, lung, and gastric cancer cell lines, S. S. Joshi, PhD, of the University of Nebraska Medical Center, Omaha, reported at the American Association of Cancer Research 89th annual meeting. (See Figure showing the effects in breast cancer cells.)

Grape seed proanthocyanidins are natural antioxidants that possess a broad spectrum of biological, pharmacological, and chemoprotective properties against free radicals and oxidative stress, he said.

The researchers, from the University of Nebraska Medical Center, Creighton University, and Georgetown University Medical Center, added the extract at two different concentrations (25 mg/L and 50 mg/L) to cultures of cell lines of human breast cancer, lung cancer, gastric cancer, and chronic myelogenous leukemia (CML).

After incubation for 72 hours, the maximum reduction in rate of cell growth in the breast cancer cell line was 43% with 25 mg/L of the extract and 47% with 50 mg/L. "Similar results were observed in the lung cells and gastric adenocar-cinoma cells, but not in the myelogenous leukemia cells," Dr. Joshi said.

The agent was also incubated with normal human gastric mucosal cells at the same concentrations. Not only were there no cytotoxic effects on these normal cells, but cell growth actually increased, by 9% at 25 mg/L of Activin and by 18% with 50 mg/L at 72 hours.

"We are particularly excited about Activin because it is a natural food substance that appears to be toxic against certain cancer cells, while actually protecting and improving the health of normal cells," Dr. Joshi said.

Dr. Debasis Bagchi, the Creighton University scientist who led the research team, said that the findings "indicate that there may be an important role for nutritional ingredients in cancer therapies as well as cancer prevention."

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy